我爱你。

嘿嘿，嘿耶。

hello， everyone， i am after tually it so happy for me。

and actually， a great onour for me to have this chance to meet you on this era terh discussion on some interesting topicwhich， which is really， really hard treatment together with gegewith is domintically bthe first ficuh。

what about we just start from the first one， which is uh uh uh HHR， the MF sic of interf STHH erterm surroy therapy， bringing long term survive benefefits to this group of patits is curcurrent ate ate treatment for advanced first AFFR enfeicwhich。

what is the state from profesior and domestially ally？ i would like to hear ar here， the interinintretrefirst for。

so HH， let's welcome proprofessor jane first。

okay。

thank you。

and thank you for the uh invitation to be here today for this discussion and uan honour pleasure to be here。

and uh yes， this year， we've had lots of chachange or lots of date and new data coming out in EGFM not muscle， one cancer， which is。

of course， exciting and exciting development fields for patients。

so the current standard care for for front line， egypt advance EGFR mutnth mussalline cancer uh is awesome ernme， a third generation eg FF reign habitit。

that is widely used in us uh uh uh in in in europe as well。

uh out other thirthirgengeneration and egyf foreign habitters。

and the uh that are that are only options used。

and some that have specific regullar approval， for example， in china and korea um but out， but in the US and in many parparof， the， but it， it's a gle single genasumr。

okay。

it that be the only option for you um um the first first line statement for these patients is the egyppartika。

is there any other options in americah ah is technicly jefet neighbor is lot named gucuneighbor fat cancer or all approved agents in the front line setting， but they are rarely ever used at this point。

uh。

because assisome mertnap has been found to be superior to jefeit nippit and a lot now than the flfloria trial has better CNS penetration than any of the other agents and is much better tolerated。

so brow of all those reasons。

it is the it is the standard of care in in the us。

thank you。

so i see okay。

so what is been in professor？

okay。

thanks for the introduction， and thanks for heving ing to join the about in now today。

so for the first question。

so in china。

uh， i think the situation is similar to the the the the united states。

uh first first n my trial IHHH the passai i chanchange the cereputive parpart。

uh uh， the t uuh， the t part， c， uh HHH ageneh and some other agents agin chuuh china available agents。

uh， all of them are approved。

now h。

the is uh pacacenenuh h emerging agent janeh IOOH uh uh h the passajaneh h gether with that one from uh uh packing union hospital。

uhlate it presented quite well in impressive。

uh there are beauty efficficccy in some EGEGR rail mutations。

that's my my my my idea。

thanks。

so we can tell that even if we have some more options， whatever the agents we can choose from the third generation ticket will be a superior。

maybe recommentation for those patients at this moment。

i think that is uum common recommendation。

think think ybe like agd that agent is still on away。

it's still not um wideapproved。

maybe。

and administrations maybe be。

well， professor or gives some more comments on this agent。

点说的设思，这是谁呀？

uh new egypt XR inhibior that has particularly good activity in the EGFRX on twenty insertion uuallong cancer as well。

some of the other eight typical mutations and uh currently uh in um um currently not approved in the US or anywhere else alis。

uh， you know exciting data on on its efficacy as post key autherapy in patients um who have egyphr x on twenty insertions as well as data in the front line setting。

uh， that has been presented some of the last couple meanings with response rates nearly uh seventy percent。

and so this agent is currently in faced three clinical development versus h platant basase chemotherapy as first line therapy for egypt excon。

most netnce most allong cancern hopefully will will be successful in that regard。

great to hear that seventy person is really uh。

i think what we are expecting are great to know that we awe will keep on looking for it， though。

result to that activity has hopefully will hold up in the face three trial。

in recent years， here has been progressing in first of target ererapies and research of new drugs， as well as exploration of different um h dalities have a great contribute to the development of in first first line treatment of the first lung cancer。

so时归时shouldshirt the。

turn maybe prophea shot can come first。

uh， the question ulot of the reason years think think tratradition ally combined like stratec CPSSH， something like uh reasreasreasin DAP plus HPSS uh HMML plus KKH uh in the in the WCLC conference this year。

uh the PUSUHHMMMP plus SSH laulus h we observe ite ite impimpsive h。

uh uh。

uh also， we have some uh some and new straratelike uh um it uh venttermap lolottuuh。

we have some some uh as a quite ADC drug uh in the EGFR field。

uh， of course， uh， the nobel agenuh h course uh in the backline settings， but we can see some uh uh new combination uh at the first first， uh， as h。

you just mentioned， uh， there very the data are very quite encouraging， and you're looking forward to this uuuh uh combinations uh so much，

but i think this topic and professior as uh uh ugreat limited by some key words， like the current so much am the first line treatment。

so。

i think ADC is not included in this question by， but we feel would like to discuss it。

so what is europe in purposes of in？

yeah， i think uh i think were 're moving towards in the first line spaces is combination strategy。

so be it with chemotherapy， like in any any jasors or nine or floror two trial readding chemomotherapy to ithe jefit neaborawesome urnap showed improvements in PFS compared to awesome merntive as first line therapy。

and so i think we're getting to the um situuwhere。

we have now a couple， different combinations that are that where there re's clinical data。

and i think we need to continue to learn on who needs these combination therapies and who doesn't and know who's most likely to benefit from them。

i think the other exciting areas that are being tested are the bd， c。

and uh， there is a her three ADC that is being tested in combination with awesome merortnate in a face， two trial in the front line setting。

um and so you know， there re's re's thersiof agents may also migrate into the front line setting over time。

and and i think will hopefully， over the next couple years have a couple of different therapeutic combination options for patients with newly diagnose sugreniny， egypt armulline cancer。

very great as uh we can see that we can't even stop the um。

topic or a stopping the imagination of of those new agents like the ADC？ but in european professagent， what were you。

as we say， the current this moment， what would you would you like to call a real breakthrough it to this moment？

um for the first line treatment of these mutton patients think the current combinations，

you know， florior two combination or the ami less certainty they improve PFS。

but we are compared to authmmernate， but we still。

patients are still relaxing from their therapies。

so we need to continue to think about what are the other uh combination approaches that we can uh employ or use in this uh in this situation and um hopefully will continue to find new new ones and ones that lead to more dable and and sustained uh clclicical clinical responses。

ABC是。

but there are all other nonol agents that are coming along as AA。

good question for for pasity。

do you think the the GFFTKTGF fit in in first generation plus third generation or second generation， plus third generation still clear out in the front line， setting or thirbeing tested，

and we ran a clinical trial， for example， of looking at awesome martin， which of fit it in the front line setting？

um and i think there part of the idea is that you can reduce the formation of some of the egia of our secondary immutations that happen in response to awesome merortaneso。

so see seven nine， seven s and others。

now what i don't know is will that combination ultimately have an impact on PFS because your。

really， only going after one resistance mechanism， you know the on target mechanism resistance to awemernative in。

so if you liminminate usmall uh uh minority resistance mechanism， does that or prevented from happening？does that is that sufficient to shift the PFS over or not？ i don't know that will wait and see for the data。

i think， in contrast， where key motherapy can affect multiple resistance mechanisms and enhancour mmer neighbor and event map that can impact egypt and met mediated resistance mechanisms。

these broader strategies， you know， we've seseen have improved PFSI have the same hope for the ADCS when combined with withus emerntive， because we know the ADC can work on multiple different resistance mechanisms。

so so can can ultimately hopefully prevent those from happening in the first place。

so think think of these broader approaches uh maybe better， but will will wait and see as the data evolves。

这个是点。

what more about this topic？do you really think in the future？look， as far we can see does does ADC uh agents has to be usely a combination with with uh f situation。

if we set it into the first line setting because just as you referred， it can do with many like the HFA situuh h uh h， the situuuh h uuuh be acactive with the。

we say toanina eve patients and。

do you think it will take the place in the first alline treatment of the e fatic guy in the future？maybe just i don't you to take the place of EGFRTKSI think that's going to be difficult to displace。

it may add to EGFR thk y。

so the other other avenue is that it's other second line therapy。

so you know， difficult second line therapy after failure first time EFT therapso be be m of therapy。

planned basase chethererapnow maybe be that could be a place for ADC could be uh uh effective about second line therapies。

and there is a with with DEGADC the partrite um diacact。

there is a face three trial ongoing in the second line setting post EGFR atc randomzing， the her three DXT， the three three DCCHH patience to that or to plplned basase chemoof therapy。

so。

we'll see when that study， hopefully， we'll ll get an idea of that study over the next year year 're in half。

and that 'll help us define the role of an adc in that second line setting。

and in the meantime， there are trials combining them in the front line setting。

so i'll see where the box， but i don't think it'll replace EGFRTKI。

could it add to an EGFRTKI？maybe then if we take them together，

do we need to um put some more worries about the toxi cities as now to opinion it CS，

of course， some。

toxicties， including sure a chemotherapy like toxiccities， oh many， even which are hemothologic toxiccities and some nogia vomining。

but then ADC um can also give uh uh numaniitas or industsocial lung disease and as caneneg of our TKI。

so i think that's the。

thing that we need to watch out for the combination strategy is that is， are you going to end up in a situation with greater degree of um ILD with an ADC combination， compare to asingle ageney FRTKR single legiand ADC is the combination lead to more ILDI will know that in the florior two trial， the combination of chemotherapy。

so platant， perattractic and awesome murnity did not increase the rate of ILD compared to asome mermerand beloans。

at least we know that piece of information。

but。

but i'll be important to continue to monitor uh these。

because as you point out， you know， everything everything has cost， everything has a toxiccost。

so we have to monitor both efficcacy and toxicity。

you have to dep therapies that are efffications， but not not not at the cost of overwhelming toxicity ced。

okay？